BRCA1 and peritoneum cancer: A recent therapeutic breakthrough has been provided by PARP inhibitors for treatment or maintenance of BRCA1/2-mutated patients (about 15–20% of patients), and it is now approved for epithelial ovarian, fallopian tube and primary peritoneal cancer, as both treatment and maintenance [39].